Synthesis, characterization and anticancer effect of doxorubicin-loaded dual stimuli-responsive smart nanopolymers

• Ömür Acet,
• Pavel Kirsanov,
• Burcu Önal Acet,
• Inessa Halets-Bui,
• Dzmitry Shcharbin,
• Şeyda Ceylan Cömert and
• Mehmet Odabaşı

Beilstein J. Nanotechnol. 2024, 15, 1189–1196, doi:10.3762/bjnano.15.96

• response to external stimuli [21][22]. Different “smart” polymeric nanoparticle systems have been described in the literature, which might respond to both internal and external stimuli to release drugs. Remarkable developments have been made regarding in vitro and in vivo drug release with varying drug

Recent updates in applications of nanomedicine for the treatment of hepatic fibrosis

• Damai Ria Setyawati,
• Fransiska Christydira Sekaringtyas,
• Riyona Desvy Pratiwi,
• A’liyatur Rosyidah,
• Rohimmahtunnissa Azhar,
• Nunik Gustini,
• Gita Syahputra,
• Idah Rosidah,
• Etik Mardliyati,
• Tarwadi and
• Sjaikhurrizal El Muttaqien

Beilstein J. Nanotechnol. 2024, 15, 1105–1116, doi:10.3762/bjnano.15.89

• as an absorption enhancer [51]. The therapeutic potential of curcumin using nanoformulations was reviewed by several researchers, summarizing recent curcumin encapsulation works on various NP platforms (liposomes, solid lipid NPs, micelles, and polymeric NPs) [52][53]. For example, polymeric

• nanoparticle-encapsulated curcumin (NanoCurc™) could ameliorate CCl4-induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines [54]. The polymer platform of NanoCurc™ consists of N-isopropylacrylamide, vinylpyrrolidone, and acrylic acid and was selected because of its capability to

Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics

• Mamta Kumari,
• Amitabha Acharya and
• Praveen Thaggikuppe Krishnamurthy

Beilstein J. Nanotechnol. 2023, 14, 912–926, doi:10.3762/bjnano.14.75

• conditions for coupling. Shi et al. developed a polymeric nanoparticle system using biodegradable graft copolymers of (poly(TMCC-co-LA)-g-PEG-furan) to conjugate anti-HER2 antibodies through a Diels–Alder reaction. They used furan groups (diene), which are accessible for reaction with antibodies

Polymer nanoparticles from low-energy nanoemulsions for biomedical applications

• Santiago Grijalvo and
• Carlos Rodriguez-Abreu

Beilstein J. Nanotechnol. 2023, 14, 339–350, doi:10.3762/bjnano.14.29

• the treatment of a vast number of diseases including cancer and neurological diseases. Continuous effort in the field of designing novel polymeric nanoparticle-based formulations might contribute to reduce the existing gap between preclinical and clinical models. This extensive research might overcome

Rational design of block copolymer self-assemblies in photodynamic therapy

• Maxime Demazeau,
• Laure Gibot,
• Anne-Françoise Mingotaud,
• Patricia Vicendo,
• Clément Roux and
• Barbara Lonetti

Beilstein J. Nanotechnol. 2020, 11, 180–212, doi:10.3762/bjnano.11.15

Atomic-level characterization and cilostazol affinity of poly(lactic acid) nanoparticles conjugated with differentially charged hydrophilic molecules

• María Francisca Matus,
• Martín Ludueña,
• Cristian Vilos,
• Iván Palomo and
• Marcelo M. Mariscal

Beilstein J. Nanotechnol. 2018, 9, 1328–1338, doi:10.3762/bjnano.9.126

• suggest that the combination of molecular dynamics ReaxFF simulations and blind docking techniques can be used as an explorative tool prior to experiments, which is useful for rational design of new drug delivery systems. Keywords: drug delivery; PEGylated nanoparticle; PLA; polymeric nanoparticle

Hematopoietic and mesenchymal stem cells: polymeric nanoparticle uptake and lineage differentiation

• Ivonne Brüstle,
• Thomas Simmet,
• Gerd Ulrich Nienhaus,
• Katharina Landfester and
• Volker Mailänder

Beilstein J. Nanotechnol. 2015, 6, 383–395, doi:10.3762/bjnano.6.38

Nanoencapsulation of ultra-small superparamagnetic particles of iron oxide into human serum albumin nanoparticles

• Matthias G. Wacker,
• Mahmut Altinok,
• Stephan Urfels and
• Johann Bauer

Beilstein J. Nanotechnol. 2014, 5, 2259–2266, doi:10.3762/bjnano.5.235

• systemic exposition of patients with the carrier [6]. Human serum albumin (HSA) represents a promising candidate that binds a wide range of compounds with different physicochemical characteristics. In 2007, with Abraxane®, a first polymeric nanoparticle formulation consisting of this material has been